(Q37882756)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

meta-analysis

0 references

title

Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Jennifer Hirst

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

C L Blacklock

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

K S Taylor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

R J Stevens

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A J Farmer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1182-1187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (IN

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2011.03341.X

10.1111/J.1464-5491.2011.03341.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21627686%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference